공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

아스페르길루스증 : 파이프라인 리뷰

Aspergillosis (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 232851
페이지 정보 영문 206 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


아스페르길루스증 : 파이프라인 리뷰 Aspergillosis (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 206 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

아스페르길루스증은 아스페르길루스균에 의한 감염 또는 알레르기 반응입니다. 증상에는 기침, 발열, 두통, 권태감, 체중 감소 및 흉부 통증 등이 있습니다. 이 질환은 자기면역계의 약화시 및 백혈구 감소시 천식, 장기간의 코르티코스테로이드 치료 등에 의해 이환할 수 있습니다.

세계 아스페르길루스증(Aspergillosis) 치료제 파이프라인 제품 개요를 정리했으며, 제품 개발, 출시 최신 동향, 임상시험 각 단계 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

아스페르길루스증 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 대학/연구기관에서 개발된 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

아스페르길루스증 치료제 개발 참여 기업

  • Amplyx Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Biomar Microbial Technologies
  • Biosergen AS
  • Cidara Therapeutics Inc
  • F2G Ltd
  • Hsiri Therapeutics LLC
  • iCo Therapeutics Inc.
  • Matinas BioPharma Holdings Inc
  • Merck & Co Inc
  • Nanomerics Ltd
  • Novabiotics Ltd
  • Pulmatrix Inc
  • Pulmocide Ltd
  • Scynexis Inc
  • Sealife PHARMA GMBH
  • Sigma-Tau SpA
  • Vical Inc
  • Visterra Inc

약제 개요

아스페르길루스증 : 휴지 상태의 프로젝트

아스페르길루스증 : 개발이 중지된 제품

아스페르길루스증 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Aspergillosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Aspergillosis - Pipeline by AbGenics Life Sciences Pvt Ltd, 2021
  • Aspergillosis - Pipeline by ABIONYX Pharma SA, 2021
  • Aspergillosis - Pipeline by Acea Biotech Inc, 2021
  • Aspergillosis - Pipeline by Argenx SE, 2021
  • Aspergillosis - Pipeline by Basilea Pharmaceutica Ltd, 2021
  • Aspergillosis - Pipeline by Bio-Synectics Inc, 2021
  • Aspergillosis - Pipeline by Biosergen AS, 2021
  • Aspergillosis - Pipeline by Cidara Therapeutics Inc, 2021
  • Aspergillosis - Pipeline by CSPC Pharmaceutical Group Ltd, 2021
  • Aspergillosis - Pipeline by F2G Ltd, 2021
  • Aspergillosis - Pipeline by Galephar Pharmaceutical Research Inc, 2021
  • Aspergillosis - Pipeline by Immupharma Plc, 2021
  • Aspergillosis - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2021
  • Aspergillosis - Pipeline by Matinas BioPharma Holdings Inc, 2021
  • Aspergillosis - Pipeline by Merck & Co Inc, 2021
  • Aspergillosis - Pipeline by Molecular Express Inc, 2021
  • Aspergillosis - Pipeline by Nanomerics Ltd, 2021
  • Aspergillosis - Pipeline by Novabiotics Ltd, 2021
  • Aspergillosis - Pipeline by Pfizer Inc, 2021
  • Aspergillosis - Pipeline by Pulmocide Ltd, 2021
  • Aspergillosis - Pipeline by Pulmonomy Inc, 2021
  • Aspergillosis - Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Aspergillosis - Pipeline by Satellos Bioscience Inc, 2021
  • Aspergillosis - Pipeline by Scynexis Inc, 2021
  • Aspergillosis - Pipeline by Shaanxi Synthetic Pharmaceutical Co Ltd, 2021
  • Aspergillosis - Pipeline by Stadius Biopharma LLC, 2021
  • Aspergillosis - Pipeline by TFF Pharmaceuticals Inc, 2021
  • Aspergillosis - Pipeline by Trilogy Therapeutics Inc, 2021
  • Aspergillosis - Pipeline by Visterra Inc, 2021
  • Aspergillosis - Dormant Projects, 2021
  • Aspergillosis - Dormant Projects, 2021 (Contd..1)
  • Aspergillosis - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Aspergillosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Drugs In Development, 2021, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 3, 3, 1, 18 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Aspergillosis - Overview
  • Aspergillosis - Therapeutics Development
  • Aspergillosis - Therapeutics Assessment
  • Aspergillosis - Companies Involved in Therapeutics Development
  • Aspergillosis - Drug Profiles
  • Aspergillosis - Dormant Projects
  • Aspergillosis - Discontinued Products
  • Aspergillosis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q